Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Phase 2 Trial of JKN24011 in COPD
Sponsor: Joincare Pharmaceutical Group Industry Co., Ltd
Summary
A Randomized, Double-Blind, Placebo-Controlled Phase II Study to Evaluate the Efficacy and Safety of Subcutaneous JKN24011 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Official title: A Randomized, Double-Blind, Placebo-Controlled Phase II Study to Evaluate the Efficacy and Safety of Subcutaneous JKN24011 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Key Details
Gender
All
Age Range
40 Years - 80 Years
Study Type
INTERVENTIONAL
Enrollment
215
Start Date
2024-08-01
Completion Date
2026-05
Last Updated
2026-02-27
Healthy Volunteers
No
Interventions
JKN24011
JKN24011 subcutaneous injection,Q4W
Placebo
Placebo subcutaneous injection,Q4W
Locations (1)
Huadong Hospital, Fudan University
Shanghai, China